media – Page 45 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Scientists develop new mRNA vaccine platform that can significantly enhance the body’s immune response

Yale University researchers have developed a novel mRNA vaccine platform designed to significantly enhance immune responses, improve the effectiveness of mRNA vaccines, and expand their potential for preventing and treating a variety of diseases. The study, published in the latest issue of Nature Biomedical Engineering, demonstrates that this vaccine platform technology could make future mRNA vaccines more reliable and effective. mRNA vaccines have become increasingly popular in recent years. Their principle is to provide genetic instructions to human cells, enabling them to produce specific viral proteins on their own, thereby triggering an immune response. However, this technology has limited effectiveness in treating certain diseases, prompting researchers to continuously optimize its delivery system. Researchers have found that the key to the effectiveness of mRNA vaccines lies in whether the antigens can be effectively recognized by the immune system. Antigens must appear on the cell surface to be detected by the immune ...
- Source: drugdu
- 111
- September 1, 2025
Difluprednate API Approved, Strengthening Advantages of Integrated API and Pharmaceutical Preparations

August 29, Jinyao Pharmaceutical(600488) issued an announcement. Recently, the company received the ” Chemical Raw Materials ” certificate for difluprednate approved by the State Food and Drug Administration.Approval of the Drug Marketing Application. It is understood that difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. Currently, the main dosage form on the market is eye drops, primarily used to treat inflammation and pain associated with eye surgery. According to statistics from the IQVIA database, the global sales of difluprednate preparations (including single and compound preparations) in 2023 and 2024 will be US$49 million and US$41 million, respectively. The announcement indicates that the company submitted its registration application for difluprednate API to the National Medical Products Administration (NMPA) in August 2020 and was accepted. From June to October 2022, the company completed the submission of supplementary documentation as required by the notice and recently received ...
- Source: drugdu
- 86
- September 1, 2025
【EXPERT Q&A】In what aspects is trimethylolpropane used?

Drugdu.com expert’s response: Trimethylolpropane (TMP), as a critical fine chemical product, demonstrates extensive application value across multiple industrial sectors. Its core uses can be summarized as follows: I. Resin Synthesis: A Key Raw Material for Enhancing Material Performance Alkyd and Polyurethane Resins: TMP serves as a cornerstone raw material for synthesizing alkyd and polyurethane resins. Its three hydroxymethyl groups enable cross-linking reactions with organic acids or diisocyanates, significantly improving resin hardness, abrasion resistance, chemical resistance, and weatherability. For example, in automotive coatings, TMP-containing resins enhance UV and acid rain resistance, extending vehicle lifespan. Unsaturated Polyester and Epoxy Resins: As a chain extender or cross-linker, TMP increases polymer molecular weight, enhancing mechanical properties (e.g., tensile strength, impact resistance) and thermal stability. It is widely applied in aerospace, electronics, and other high-end fields. Coatings and Inks: Optimizing Performance and Processes Coatings Industry: TMP is a vital component in high-performance coatings, improving drying ...
- Source: drugdu
- 210
- September 1, 2025
Healthy gut bacteria capsules show long-term benefits for obese teenagers

Can a capsule of healthy gut bugs change the future of obesity treatment? New findings from the University of Auckland’s Liggins Institute suggest it might. Eight years ago, 87 obese adolescents took part in a groundbreaking study to see whether fecal transfer (taking ‘good’ gut bacteria from healthy donors and giving them in capsule form to people with a less healthy microbiome) would make a difference to their health and weight. Four years later, a follow-up study, published this week in the world-leading scientific journal Nature Communications , suggests some significant health benefits from that single gut bugs transfer. In particular, the original overweight teens who received the transfer had reduced risk for a bunch of metabolic changes which can lead to heart disease, stroke and diabetes, compared with the participants who received the placebo. Obesity is a significant health problem in New Zealand and elsewhere in the world. In ...
- Source: drugdu
- 110
- August 29, 2025
Fatty Foods Might Contribute To Childhood Asthma

By Dennis Thompson HealthDay ReporterTHURSDAY, Aug. 28, 2025 (HealthDay News) — Fatty foods might contribute to asthma in children, a new study says. Fats found in certain foods are linked to neutrophilic asthma, a non-allergic type of asthma triggered by microbial and bacterial proteins, researchers reported Aug. 27 in the journal Science Translational Medicine. Specifically, a type of saturated fatty acid called stearic acid – often found in animal fat and processed foods – appears to start a chain reaction that can lead to neutrophilic asthma, researchers said. “Prior to this study, many suspected that childhood obesity was causing this form of asthma,” said senior researcher Dr. David Hill, an attending physician in allergy and immunology at Children’s Hospital of Philadelphia. “However, we were observing neutrophilic asthma in children who weren’t obese, which is why we suspected there might be another mechanism,” Hill said in a news release. “What we ...
- Source: drugdu
- 127
- August 29, 2025
Clinical research of SGC001, a drug in which Regeneron Biopharma holds a stake, is progressing smoothly.

On August 28, Rejing Bio(688068) issued an announcement that it recently received a request from a joint venture company for an innovative drugA progress report on the Phase I clinical study of SGC001 injection. The project has completed a Phase Ia clinical study in healthy volunteers, and the Phase Ib clinical study in patients with anterior ST-segment elevation myocardial infarction is progressing smoothly. Clinical observations of all subjects have been completed, and the clinical study was unblinded on August 27. SGC001 injection, developed jointly by Sungene’s R&D team and other institutions, is indicated for the emergency treatment of patients with acute myocardial infarction. The drug’s clinical trial application has been approved by the FDA and CDE, and it received FDA Fast Track designation in March 2025. Currently, complete efficacy and safety information from the Phase Ib trial will be disclosed in the official data analysis report, and will not have ...
- Source: drugdu
- 80
- August 29, 2025
Walvax Biopharma’s 23-valent pneumococcal vaccine enters the Latin American market for the first time

Recently, Yunnan Walvax BioThe 23-valent pneumococcal polysaccharide vaccine ( hereinafter referred to as ” 23-valent pneumococcal vaccine”) produced by Yuxi Walvax Biotechnology Co. , Ltd., a subsidiary of Walvax Biotechnology Co., Ltd. (hereinafter referred to as “Walvax Biotechnology”), has completed its first export delivery to El Salvador. This milestone event marks the first export of Walvax Biotechnology to El Salvador.The product officially entered the Latin American market, further expanding its global layout. According to data disclosed by Walvax Bio, as the world’s first preservative-free 23-valent pneumococcal polysaccharide vaccine, this product is suitable for children over 2 years old and high-risk adults. The cumulative global sales volume has exceeded 14 million doses. As of now, Walvax Bio has built a diversified global vaccine supply network. Its products, including 13-valent pneumococcal polysaccharide conjugate vaccine, bivalent human papillomavirus vaccine (Pichia pastoris), 23-valent pneumococcal vaccine, ACYW135 group meningococcal polysaccharide vaccine, group A and group C meningococcal ...
- Source: drugdu
- 121
- August 29, 2025
Yabao Pharmaceutical’s subsidiary, SY-005 Injection, has been approved for clinical trials in the treatment of gliomas.

On August 25, Yabao Pharmaceutical(600351) issued an announcement that its controlling subsidiary Suzhou Yabao Pharmaceutical Research and Development Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for the new indication of SY-005 injection approved and issued by the National Medical Products Administration. The approval notice allows the clinical trial of SY-005 injection for the treatment of neurological deficits after glioma surgery. The application is for the treatment of neurological deficits after glioma surgery, and the drug registration classification is a therapeutic biological product.Category 1. As of the date of this announcement, the company has invested approximately RMB 127 million in R&D for the SY-005 project. SY-005 is an innovative recombinant protein .In November 2018, the company received approval for a clinical trial for the treatment of sepsis, and this indication is currently in Phase II clinical trials. Glioma is the most common primary intracranial malignant tumor, and postoperative ...
- Source: drugdu
- 104
- August 29, 2025
Genfleet Pharmaceutical passed the Hong Kong Stock Exchange hearing

The Hong Kong Stock Exchange’s official website indicates that Jinfang Pharmaceuticals (Shanghai) Co., Ltd. has passed its hearing and is poised to list on the Hong Kong Stock Exchange. The prospectus states that Jinfang Pharmaceuticals, founded in 2017, is a biopharmaceutical company focused on developing novel treatment options for oncology (covering various lines of treatment for various solid tumors) as well as autoimmune and inflammatory diseases. Currently, Jinfang Pharmaceuticals has established a product pipeline consisting of eight drug candidates, five of which are in clinical development. Comment: Jinfang Pharmaceuticals, which has passed its Hong Kong Stock Exchange hearing, focuses on oncology and immune diseases. Its pipeline includes eight drug candidates, five of which are in clinical trials. A successful IPO could accelerate R&D, but the company faces intense competition in the field. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 83
- August 29, 2025
Xinhua Bio completed tens of millions of US dollars in Series A financing

On August 25th, Xinhua Bio announced the completion of a multi-million dollar Series A financing round. The Series A+ round was led by Xingze Capital, while the Series A round was led by Sany Innovation Investment, with participation from other existing shareholders, including Sequoia China. The funds will be primarily used to advance the company’s core pipeline into global clinical trials, accelerate research and development, and provide more effective treatment options for patients worldwide. Comment: Xinhua Biopharma received tens of millions of US dollars in Series A financing. The funds will help its core pipeline enter global clinical trials, accelerate research and development, and highlight its research and development potential and market value in fields such as tumor immunology. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 77
- August 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.